文献速递妇科

奎纳克林在子宫内膜癌中的应用:老抗疟药的新用途

Quinacrine in endometrial cancer: Repurposing an old antimalarial drug.
PubMed 文献 · Gynecol Oncol · 2017-05-22

本研究在五种子宫内膜癌细胞系中体外评估奎纳克林抑制细胞活力的作用及与化疗药的协同性,并在顺铂耐药的Hec-1B皮下小鼠模型中探讨其维持治疗作用。结果显示奎纳克林与顺铂、卡铂或紫杉醇呈强协同,联合治疗较卡铂/紫杉醇显著延长生存14周,维持治疗进一步延缓肿瘤进展并延长生存;作者认为奎纳克林可能成为化疗耐药子宫内膜癌标准化疗的重要辅助。

要点

  • 奎纳克林与顺铂、卡铂或紫杉醇在体外呈强协同,化疗最耐药细胞系协同最强。
  • 小鼠模型中奎纳克林单药或卡铂/紫杉醇未显著延缓肿瘤生长。
  • 奎纳克林联合卡铂/紫杉醇较单用卡铂/紫杉醇生存延长14周,维持治疗进一步延缓进展。

核心结论

  • 奎纳克林在体外对子宫内膜癌显示显著抗肿瘤活性,并在化疗耐药子宫内膜癌小鼠异种移植模型中作为维持治疗取得成功。
  • 这些临床前数据提示奎纳克林可能成为化疗耐药子宫内膜癌患者标准化疗的重要辅助。

研究设计与样本

  • 体外研究使用五种代表不同组织学、分级、顺铂敏感性和p53状态的子宫内膜癌细胞系:Ishikawa、Hec-1B、KLE、ARK-2和SPEC-2。
  • 采用MTT法和集落形成实验检测奎纳克林体外抑制细胞活力的能力,采用Chou-Talalay法分析奎纳克林与顺铂、卡铂或紫杉醇的协同作用。
  • 使用顺铂耐药的Hec-1B皮下小鼠模型评估奎纳克林作为维持治疗的作用。

主要发现

  • 奎纳克林与顺铂、卡铂或紫杉醇联合在体外呈强协同作用,在化疗最耐药的细胞系中协同水平最高。
  • 在异种移植模型中,奎纳克林单药治疗和卡铂/紫杉醇治疗均未显著延缓肿瘤生长。
  • 联合治疗(奎纳克林联合卡铂/紫杉醇)显著增强这些药物的抗增殖能力,与卡铂/紫杉醇相比生存延长14周。
  • 与卡铂/紫杉醇相比,奎纳克林维持治疗进一步延缓肿瘤进展并延长生存。
  • 奎纳克林与体重减轻无关,治疗期间观察到的皮肤黄染在停药后可逆。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Generate preclinical data on the effect of quinacrine (QC) in inhibiting tumorigenesis in endometrial cancer (EC) in vitro and explore its role as an adjunct to standard chemotherapy in an EC mouse model. METHODS: Five different EC cell lines (Ishikawa, Hec-1B, KLE, ARK-2, and SPEC-2) representing different histologies, grades of EC, sensitivity to cisplatin and p53 status were used for the in vitro studies. MTT and colony formation assays were used to examine QC's ability to inhibit cell viability in vitro. The Chou-Talalay methodology was used to examine synergism between QC and cisplatin, carboplatin or paclitaxel. A cisplatin-resistant EC subcutaneous mouse model (Hec-1B) was used to examine QC's role as maintenance therapy. RESULTS: QC exhibited strong synergism in vitro when combined with cisplatin, carboplatin or paclitaxel with the highest level of synergism in the most chemo-resistant cell line. Neither QC monotherapy nor carboplatin/paclitaxel significantly delayed tumor growth in xenografts. Combination treatment (QC plus carboplatin/paclitaxel) significantly augmented the antiproliferative ability of these agents and was associated with a 14-week survival prolongation compared to carboplatin/paclitaxel. Maintenance with QC resulted in further delay in tumor progression and survival prolongation compared to carboplatin/paclitaxel. QC was not associated with weight loss and the yellow skin discoloration noted during treatment was reversible upon discontinuation. CONCLUSIONS: QC exhibited significant antitumor activity against EC in vitro and was successful as maintenance therapy in chemo-resistant EC mouse xenografts. This preclinical data suggest that QC may be an important adjunct to standard chemotherapy for patients with chemo-resistant EC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kalogera E, Roy D, Khurana A, et al. Quinacrine in endometrial cancer: Repurposing an old antimalarial drug. Gynecol Oncol. 2017. PMID: 28545688. doi:10.1016/j.ygyno.2017.04.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。